ESSENTIAL ARTERIAL HIPERTENSION (AHT) AND RENAL CHRONIC SUSPENSION

Mirlind Behxheti, Nasir Behxheti

Abstract

Arterial hypertension (AHT) is a high risk factor for patients with chronic renal failure. Over 72 million people are suffering from AHT in the US. AHT usually affects most patients with chronic renal disease (Nwankwo et al., 2011). Starting in 2011, a large number of clinical practice guidelines have been published on AHT treatment in patients with chronic renal insufficiency who are involved in the maintenance of arterial pressure <140/90 mm Hg (Chobanian et al., 2003, Bansal et al., 2015)A number of major studies in patients with chronic kidney failure have verified and documented that AHT treatment significantly affects rapid prevention of disease progression. According to the guidelines of the National Kidney Disease Outcome Quality Initiative (NKF / KDOI), the AHT treatment should be <130/80 mmHg to albuminuria and when the ratio of albumin to urine - creatinine> 30 mg / g which has shown high effects on clinical results and progression slowdown compared to the results of patients with arterial pressure above 140/90 mmHg (Chobanian et al., 2003, Bansal et al., 2015). The purpose of medically-mediated treatment for a blood pressure of <140 / 90 mm Hg or the lowest possible value tolerated by the patient should be the target of primary and secondary doctors. Adequate blood pressure control usually requires pharmacological therapy (with one or two antihetertonic drugs as well as diuretic therapy) which should be adjusted according to arterial pressure values. Purpose: The purpose of this research is to verify the influence and effects of antihypertensive in the treatment of essential AHT in patients with CRF. Material and Methods: In the "cross-section" study, 300 patients (170 males and 130 females) with mean median age of 55.7 ± 9.5 years and 200 healthy individuals (100 males and 100 women) with mean age: 56.8 ± 12 years who served as a control group for comparing values ??obtained from patients with CRF and HTA. Patients with CRF and AHT were treated with antihypertensive (ACE inhibitors and ARBs) within 12 meals - with three measurements (every 4 months). Patients were divided according to the degree of hypertension and according to the JNC-VII joint report of the national committee for the prevention and detection of AHT in 2003. The examined patients examined proteinuria, serum urea, serum creatine, uric acid, electrolyte and lipid profile in order to verify their influence on the appearance of arterial hypertension as complementary factors in the etiology of CRF. Conclusion: In conclusion we can conclude that early detection of AHT etiology by AHT and quality treatment should be the first step of primary and secondary doctors a powerful AHT control in order to prevent rapid progression of the disease and its complications.

Pages: 91 - 96